Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | CTSC | P53634 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924826 | 1.00 | MME (0.65) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL11211282 | 1.00 | MME (0.65) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL31215125 | 0.96 | MME (0.60) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL30735714 | 0.96 | MME (0.60) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL30595093 | 0.94 | MME (0.59) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL31215069 | 0.94 | MME (0.59) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL29892331 | 0.93 | MME (0.58) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL31096839 | 0.92 | MME (0.56) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL7325824 | 0.92 | MME (0.56) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL30567413 | 0.92 | MME (0.67) | MMEALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| CN-120131737-A | Composition for improving immunity based on astragalus natural ingredients and preparation method thereof | 蔓泰(北京)健康科技有限责任公司 | 2025-06-13 | — | — | CN | claimed |
| WO-2024259525-A1 | NANOPARTICLES COMPRISING N,N,N-TRIMETHYL CHITOSAN COATED WITH PEPTIDE AGONISTS OF KININ B1 OR B2 AND/OR PEPTIDE ANTAGONISTS OF KININ B1 FOR TRANSVASCULAR DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SANTE ET HUMAINES, S.E.C. (CA) | 2024-12-26 | — | — | WO | claimed |
| WO-2024162422-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | ハウス食品グループ本社株式会社 | 2024-08-08 | — | — | WO | claimed |
| WO-2024162421-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | ハウス食品株式会社 | 2024-08-08 | — | — | WO | claimed |
| CN-117815402-A | Coupling medicine of targeting STAT3 protein and application thereof | 国家纳米科学中心 | 2024-04-05 | — | — | CN | claimed |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-02-01 | — | — | US | claimed |
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | UNIVERSITY OF SOUTH ALABAMA (US) | 2024-01-25 | — | — | US | claimed |
| CN-116102635-A | Cathelicidin family polypeptide from aquatic mammal, and preparation method and application thereof | 中国药科大学 | 2023-05-12 | — | — | CN | claimed |
| US-20220401585-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | RIGSHOSPITALET (DK) | 2022-12-22 | — | — | US | claimed |
| EP-4081256-A1 | UPAR-TARGETED PHOTOTHERMAL OPTICAL PROBES FOR PHOTOTHERMAL THERAPY | Rigshospitalet (DK) | 2022-11-02 | — | — | EP | claimed |
| US-20220257799-A1 | A RECEPTOR-TARGETING CONJUGATE WITH AN EFFECTIVE PHARMACOKINETIC PROFILE | FLUOGUIDE A/S (DK) | 2022-08-18 | — | — | US | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| CN-106537145-A | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2017-03-22 | — | — | CN | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-1981000847-A1 | PEPTIDES HAVING IMUNOSTIMULATING PROPERTIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PASTEUR INSTITUT (FR) | 1981-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024409-A1 | N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | MME 49/4885ALPI 1972/4885PKM 4202/4885 |
| US-20240033365-A1 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | FPR1, FPR2, FPR3 | MME 200/4885ALPI 1955/4885PKM 4093/4885 |
| US-20220401585-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | PLAUR, PLAU, PLG | MME 214/4885ALPI 4409/4885PKM 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.